Ask AI
ProCE Banner Series

Know Your ADCs: Nursing Perspectives on Antibody-Drug Conjugates Targeting TROP-2 in Solid Tumors

Join us either in person or virtually for this live, 1.5-hour, CE-certified symposium where experts will prepare oncology nurses to discuss emerging TROP2-targeted antibody–drug conjugates (ADC) with their patients, including what an ADC is; their role in the treatment of tumors expressing TROP2, with a focus on breast, lung, and genitourinary cancers; and, how to monitor for and manage associated toxicities. Bring your questions for the experts, and after the meeting, download the slides for use in your clinic.

To Register: Please click the green “Learn More” button below. On the next page, select either Register for In-person Event or Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

For more information on ONS’ vaccination and mask requirements, please visit: ONS’ website

Meeting space has been assigned to provide a Symposium supported by Gilead Sciences, Inc. during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26 – April 30, 2023, in San Antonio, TX. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.

  ANCC
Who Should Attend

This educational program is intended for oncology nurses, nurse practitioners, clinical nurse specialists, and other healthcare professionals who care for patients with solid tumors.

All Events

Know Your ADCs: Nursing Perspectives on Antibody-Drug Conjugates Targeting TROP-2 in Solid Tumors

Past Events

April

28

2023

6:00 PM - 7:30 PM Central Time (CT)

In-personVirtual

San Antonio Marriott Rivercenter, 101 Bowie Street, San Antonio, Texas 78205

Topics

  • Welcome and Introduction
  • ADC Basics and Their Role in the Treatment of Tumors Expressing TROP2
  • Clinical Impact of TROP2-Targeting ADCs in Breast Cancer
  • Clinical Impact of TROP2-Targeting ADCs in Genitourinary Cancers
  • Preparing for the Integration of TROP2-Targeting ADCs in Lung Cancer
  • Identification and Management of Adverse Events with TROP2-Targeting ADCs
  • Final Panel Discussion and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of oncology nurses, nurse practitioners, and clinical nurse specialists to apply and explain available clinical data on novel and emerging therapies to individualize care for patients with solid tumors on or eligible for treatment with TROP2-targeted therapies.

Target Audience
This educational program is intended for oncology nurses, nurse practitioners, clinical nurse specialists, and other healthcare professionals who care for patients with solid tumors.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Compare the unique mechanism of action between the antibody-drug conjugates sacituzumab govitecan and datopotamab deruxtecan to each other and cytotoxic chemotherapy
  • Evaluate individualized treatment strategies with ADCs targeting TROP2 for patients with breast cancer and NSCLC considering recent clinical data and approved indications
  • Explain to patients the role of TROP2-targeting ADCs after disease progression on targeted therapeutics or immune checkpoint inhibitor therapies
  • Manage patients experiencing adverse events associated with ADCs targeting TROP2, including assessment of physical complaints, radiologic imaging, and lab value interpretation

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Gilead Sciences, Inc.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191